பிராண்டட் ஜெநெரிக்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிராண்டட் ஜெநெரிக்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிராண்டட் ஜெநெரிக்ஸ் Today - Breaking & Trending Today

Ipca Laboratories share price: Buy Ipca Laboratories, target price Rs 2400: Motilal Oswal


Motilal Oswal has buy call on
Ipca Laboratories Ltd. with a target price of Rs 2400. The current market price of Ipca Laboratories Ltd. is Rs 2066.05. Time period given by analyst is one year when Ipca Laboratories Ltd. price can reach defined target.
Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 26410.61 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 1134.58 Crore, down -20.39 % from last quarter Total Income of Rs 1425.21 Crore and up 4.33 % from last year same quarter Total Income of Rs 1087.49 Crore. Company reported net profit after tax of Rs 163.70 Crore in latest quarter. ....

Motilal Oswal , Ipca Laboratories Ltd , Ipca Laboratories , Laboratories Ltd , Mid Cap , Consolidated Total Income , Total Income , Branded Generics , Ipca Laboratories Share Price , Stocks To Buy , Market News , மோட்டிலால் ஒசுவள் , இப்க ஆய்வகங்கள் லிமிடெட் , இப்க ஆய்வகங்கள் , ஆய்வகங்கள் லிமிடெட் , நடுவில் தொப்பி , தொகுக்கப்பட்டு மொத்தம் வருமானம் , மொத்தம் வருமானம் , பிராண்டட் ஜெநெரிக்ஸ் , ஸ்டாக்ஸ் க்கு வாங்க , சந்தை செய்தி ,

Broker's call: Ipca Lab (Buy) - The Hindu BusinessLine


CMP: ₹2,153.75
From our interaction with the management, we believe Ipca Laboratories (IPCA) has enough levers to outperform the market in Domestic Formulations (DF) and Branded Generics exports, with good visibility in the Institutional business and continued momentum in the API segment.
IPCA has witnessed sustained growth momentum in the Pain segment. It has posted market share gains, on account of the pandemic, in products wherein smaller companies have been unable to meet supply requirements. Moreover, higher prescriptions for established brands such as Zerodol have enhanced growth prospects for IPCA in this segment.
Led by an investment of ₹400 crore toward capacity enhancement as well as the ongoing backward integration, we believe IPCA’s API business (25 per cent of sales) would sustain the growth momentum over the next 3–5 years. ....

United Kingdom , Motilal Oswal , Ipca Laboratories , Domestic Formulations , Branded Generics , Ipca Lab , Broker 39s Call , Api Segment , Branded Generics Exports , ஒன்றுபட்டது கிஂக்டம் , மோட்டிலால் ஒசுவள் , இப்க ஆய்வகங்கள் , உள்நாட்டு சூத்திரங்கள் , பிராண்டட் ஜெநெரிக்ஸ் , இப்க ஆய்வகம் ,

Branded Generics Market is Projected to Grow Massively in Near Future – KSU


The 
Branded Generics Market research report thoroughly explains each and every aspect related to the Global Branded Generics Market, which facilitates the report’s reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.
Branded Generics Market Insight:
Global Branded Generics Market is expected to rise from its initial estimated value of USD 232.83 billion in 2018 to a projected value of USD 421.15 billion by 2026, registering a CAGR of 7.69% in the forecast period of 2019-2026. This rise in market value can be attributed to growing need for cheaper treatment options and pharmaceutical drugs required by patients. ....

United States , Hong Kong , United Kingdom , South Africa , Saudi Arabia , Zydus Cadila , Asia Pacific , Stada Arzneimittel , Sun Pharmaceutical Industries Ltd , Teva Pharmaceutical Industries Ltd , Pfizer Inc , Aspen Holdings , Bausch Health , Apotex Inc , Lupin Pharmaceuticals Inc , Cipla Inc , Eris Lifesciences , Research Methodology , Market Research , Contents Of This Premium Research , Reddy Laboratories Ltd , Branded Generics Market , Global Branded Generics Market , Generics Market Insight , Including Full , Key Players ,

Nifty Pharma index surges 4%; Sun Pharma, Cipla hit 52-week highs


Shares of pharmaceutical companies were in focus at the bourses on Wednesday, with the Nifty Pharma surging 4 per cent after a consolidating in the last couple of days.
Sun Pharmaceutical Industries and Cipla rallied 6 per cent each, hitting their respective 52-week highs on the National Stock Exchange (NSE) in intra-day trade. Torrent Pharmaceuticals and Dr Reddy’s Laboratories were up 5 per cent, while Divis Laboratories, Lupin, Cadila Healtchare and Biocon from the pharma index were up in the range of 3 per cent to 4 per cent.
At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index. The pharma index hit an intra-day high of 12,896.90, just 4.5 per cent away from its record high level of 13,476.80, touched in January 2021. ....

Nirmala Sitharaman , Ajanta Pharma , Cadila Healtchare , Aatmanirbhar Swasth Bharat Yojana , Torrent Pharmaceuticals , Sun Pharmaceutical Industries , Union Budget , National Stock Exchange , Nifty Pharma , Pharmaceutical Industries , Divis Laboratories , Unichem Laboratories , Granules India , Indoco Remedies , Sequent Scientific , Neuland Laboratories , Jubilant Life Sciences , Finance Minister Nirmala Sitharaman , Nirbhar Swasth Bharat Yojana , Branded Generics , Motilal Oswal Securities , Asia Branded Generics , அஜந்தா பார்மா , நீரோடை மருந்துகள் , சூரியன் மருந்து தொழில்கள் , தொழிற்சங்கம் பட்ஜெட் ,